LivaNova’s (LIVN) Buy Rating Reaffirmed at Needham & Company LLC

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports. They currently have a $75.00 target price on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 39.98% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus boosted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. The Goldman Sachs Group started coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price target for the company. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Robert W. Baird lifted their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Stock Performance

Shares of LIVN opened at $53.58 on Tuesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The stock has a market capitalization of $2.91 billion, a price-to-earnings ratio of 127.57 and a beta of 1.01. LivaNova has a 52-week low of $42.75 and a 52-week high of $64.47. The stock’s 50-day simple moving average is $51.47 and its 200 day simple moving average is $52.98.

Institutional Investors Weigh In On LivaNova

Several hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its position in LivaNova by 88.6% in the 1st quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock worth $2,356,000 after buying an additional 19,783 shares during the last quarter. Texas Permanent School Fund Corp lifted its holdings in shares of LivaNova by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 47,147 shares of the company’s stock worth $2,637,000 after acquiring an additional 620 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of LivaNova by 4.7% in the 1st quarter. ProShare Advisors LLC now owns 12,378 shares of the company’s stock valued at $692,000 after purchasing an additional 561 shares in the last quarter. Entropy Technologies LP bought a new position in shares of LivaNova during the 1st quarter valued at $295,000. Finally, State Board of Administration of Florida Retirement System raised its position in LivaNova by 13.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 17,542 shares of the company’s stock worth $981,000 after purchasing an additional 2,060 shares during the period. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.